Laura Brege

Senior Advisor at Second Genome, Inc.

Laura Brege

Laura Brege

Senior Advisor at Second Genome, Inc.

Overview
Career Highlights

Onyx Pharmaceuticals, Inc.
COR Therapeutics, Inc.
Flextronics Corp.

RelSci Relationships

1387

Number of Boards

20

Birthday

1958

Age

63

Relationships
RelSci Relationships are individuals Laura Brege likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at ACADIA Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Chairman at HLS Therapeutics, Inc.

Relationship likelihood: Strong

Chairman, Chief Executive & Operating Officer at Pacira Biosciences, Inc.

Relationship likelihood: Strong

Former Co-Founder & Partner at New Leaf Venture Partners LLC

Relationship likelihood: Strong

Director, President & Chief Executive Officer at Panbela Therapeutics, Inc.

Relationship likelihood: Strong

Director at Nomis Solutions, Inc.

Relationship likelihood: Strong

Managing Director, T1D Fund at JDRF International

Relationship likelihood: Strong

Founder at Akoya Biosciences, Inc.

Relationship likelihood: Strong

Former Vice President & General Manager at Smithkline Beecham Pharmaceuticals (Canada)

Relationship likelihood: Strong

Former Chief Operating Officer at Immunex Corp.

Relationship likelihood: Strong

Paths to Laura Brege
Potential Connections via
Relationship Science
You
Laura Brege
Senior Advisor at Second Genome, Inc.
Education
MBA
Class of 1982

The University of Chicago Booth School of Business is a graduate business school located in Chicago, Illinois, at the University of Chicago. Formerly known as the University of Chicago Graduate School of Business, Chicago Booth is the second-oldest business school in the U.S., the first such school to offer an Executive MBA program, and the first to initiate a Ph.D. program in business. The school was renamed in 2008 following a $300 million endowment gift to the school by alumnus David G. Booth. The school has the third-largest endowment of any business school. The school's flagship campus is located in the Hyde Park neighborhood of Chicago on the main campus of the university. The school also maintains additional campuses in London and Asia (originally Singapore, but in July 2013 a move to Hong Kong was announced), as well as in downtown Chicago on the Magnificent Mile. In addition to conducting graduate business programs, the school conducts research in the fields of finance, economics, quantitative marketing research, and accounting. Chicago Booth is currently ranked first in the United States by Bloomberg Businessweek and first globally by the Economist.

Career History
Senior Advisor
Current

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

Member, Board of Directors & Audit Committee
Current

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Member, Board of Directors & Audit Committee
Current

Pacira Pharmaceuticals, Inc. develops and manufactures injectable and sustained release therapeutic products. It focuses on clinical and commercial development activities by understanding the needs of the acute care market. The company was founded in March 2007 and is headquartered in San Diego, CA.

Boards & Committees
Member, Board of Directors
2012 - Prior

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.

Member, Board of Directors
2011 - Prior

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. At Onyx, we are grounded in three leadership hallmarks that guide how we manage our business and build value for patients and shareholders: innovation, patient-centeredness and stewardship.

Presidential Trustee
Current

Established in 1945 by President John C. Baker, The Ohio University Foundation serves as the fund raising arm of Ohio University. The Foundation is an institutionally-related, nonprofit, tax exempt, 501(c)(3) organization, and is the repository for all private gifts to Ohio University through annual giving programs, capital and special campaigns, and planned or deferred gifts such as bequests and trusts. Contributions to The Ohio University Foundation are tax deductible to the extent provided by law.

Member, Board of Directors
Prior

BayBio brings together the collective strength and experience of the world’s most innovative and productive life science cluster, helping companies grow, connect and advocate to solve some of humanity’s most pressing challenges. BayBio provides comprehensive support and solutions tailored to the unique needs of nearly 1000 Bay Area life science companies and institutions, delivering tangible value through group purchasing savings, capital access, government affairs & advocacy, networking and best-practice sharing. BayBio also supports the future of bioscience innovation through the BayBio Institute’s work in science education, career development and entrepreneurship.

Political Donations
$500
2008

Former President of United States

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Laura Brege. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Laura Brege's profile does not indicate a business or promotional relationship of any kind between RelSci and Laura Brege.